The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
we frequently use the same medications that we've described before but we rely on more of those brain modulatory drugs dcas are the big um another one like the loxitine which is in the class of anti-depressants but it's a little cleaner fewer side effects it's a serotonin norepinephrine reuptake inhibitor this is actually a drug that got FDA approval for pain and so we go to this a lot
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
So we go to this a lot.